表紙
市場調查報告書
商品編碼
1035796

紫質症:開發平台評估,開發業者趨勢與競爭情形(2021年∼2031年)

Porphyria: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031

出版日期: | 出版商: Roots Analysis | 英文 124 pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

VISUALS

本報告提供紫質症的全球市場調查,市場概要,以及各類藥物,各紫質症類型,各給藥途徑,各地區的趨勢,及加入此市場的主要企業簡介等資訊。

目錄

第1章 背景

  • 環境
  • 計劃報告

第2章 摘要整理

第3章 簡介

第4章 市場形勢

  • 紫質症治療藥的市場形勢
  • 紫質症治療藥開發業者的市場形勢

第5章 案例研究

  • 結束及休止計劃相關案例研究

第6章 主要市場洞察

  • 臨床試驗分析
  • KOL分析
  • 企業的競爭力分析
  • 出版物分析
  • 夥伴關係與合作

第7章 企業簡介

  • Agios Pharmaceuticals
  • Alnylam Pharmaceuticals
  • Clinuvel Pharmaceuticals
  • Mitsubishi Tanabe Pharma
  • Moderna Therapeutics
  • Palatin Technologies
  • Recordati Rare Diseases

第8章 市場預測

  • 預測的藥物和銷售額預測
    • GIVLAARI(R)
    • Panhematin(TM)
    • SCENESSE(R)
    • MT-7117
    • Colestid
    • HARVONI(R)
  • 到2030年的全球市場預測
  • 各類藥物分佈
  • 各紫質症類型分佈
  • 各給藥途徑分佈
  • 各地區分佈

第9章 附錄

  • 臨床試驗分析
  • 出版物分析
  • 圖的清單
  • 企業和組織的清單
  • 出版物分析
  • 圖的清單
  • 企業和組織的清單
目錄

VISUALS

Overview:

The "Porphyria: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030" report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Porphyria.

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product's mechanism of action, dosage and administration, and pharmacological studies, regulatory milestones, and other development activities.

One of the key objectives of the report was to estimate the existing market size and the future opportunity of therapies for Porphyria, over the next decade. Based on multiple parameters, such as disease prevalence, anticipated adoption of the forecasted therapies and the likely selling price of such therapeutic products, we have provided informed estimates on the evolution of the market for the period 2021-2030.

Scope of the Report:

The "Porphyria Targeting Therapies Market by Type of Drug Class (Biologics and Small Molecules), Type of Porphyria (Acute Hepatic Porphyria, Acute Intermittent Porphyria, Erythropoietic Protoporphyria, Hereditary Porphyria, Porphyria Cutanea Tarda, Variegate Porphyria and X-Linked Protoporphyria), Route of Administration (Oral, Intravenous and Subcutaneous) and Key Geographical Regions (US, Canada, UK, France, Germany, Italy, Spain, Netherlands, Australia and Japan): Industry Trends and Global Forecasts: Industry Trends and Global Forecasts, 2021-2030" report features an extensive study of the current market landscape and future opportunity for the players engaged in developing porphyria targeting therapies. The study presents an in-depth analysis, highlighting the capabilities of various developers engaged in this domain. Amongst other elements, the report features:

  • A detailed review of the current market landscape of porphyria targeting therapies providing information on phase of development, drug class (biologic, small molecule), route of administration (oral, intravenous, subcutaneous), mechanism of action, type of porphyria (Acute Hepatic Porphyria, Acute Intermittent Porphyria, Congenital Erythropoietic Porphyria, Erythropoietic Protoporphyria, Hereditary Coproporphyria, Porphyria Cutanea Tarda, Variegate Porphyria, X-Linked Protoporphyria) , drug designations (breakthrough therapy designation, fast track, orphan drug designation)
  • A detailed review of the current market landscape of porphyria targeting therapies developers providing information on year of establishment, headquarters, company size (in terms of employee count), type of player (industry, non-industry) and ownership (public, private, non-profit)
  • An insightful case study on terminated and dormant programs highlighting the terminated and dormant clinical studies in this domain.
  • An in-depth clinical trial analysis providing information on trial status, trial registration year, trial phase, number of patients enrolled, geographical distribution, type of treatment, type of sponsors, active players, study design, type of allocation, type of intervention and type of porphyria.
  • An insightful key opinion leader analysis highlighting the key principal investigators, appointed to lead clinical investigations and examine therapies targeting porphyria using our proprietary scoring based on parameters such as number of publication, number of citations, number of clinical trials, work experience, number of affiliated companies, number of LinkedIn connections and number of affiliated organizations.
  • An insightful competitiveness analysis of the players engaged in the development of therapies targeting porphyria, taking into consideration their portfolio strength (in terms number of drugs in pipeline, phase of development and drug class) , number of partnerships, patent portfolio, google hits, year of establishment and size of the company.
  • An analysis of publications that have been published related to this domain based on key parameters such as year of publication, top authors, top journal and emerging focus area.
  • An analysis of the partnerships that have been inked by stakeholders in this domain, in the period between 2010 and 2020, covering product development and commercialization agreement, clinical trial agreement, product development agreement, product licensing agreement and other relevant types of deals.
  • Elaborate profiles of key players developing porphyria targeting therapies. Each company profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key members of the executive team, financial / funding information and product portfolio) , recent developments and an informed future outlook.

One of the key objectives of this report was to estimate the existing market size and to estimate the opportunity associated with the porphyria market We have developed informed estimates on the financial evolution of the market, over the period 2021-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] drug class (biologics and small molecules), [B] route of administration (oral, intravenous and subcutaneous) , [C] type of porphyria (Acute Hepatic Porphyria, Acute Intermittent Porphyria, Erythropoietic Porphyria, Hereditary Porphyria, Porphyria Cutanea Tarda, Variegate Porphyria And X-Linked Porphyria) , [D] regional distribution (US, Canada, UK, Germany, France, Italy, Spain, Netherlands, Australia and Japan) ,. In order to account for future uncertainties and to add robustness to our forecast model, we have provided three scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered:

  • What are the prevalent R&D trends related to Porphyria?
  • What are the key challenges faced by stakeholders engaged in this domain?
  • What are the principal therapies developed by the companies in this domain?
  • Who are the leading industry and non-industry players in this market?
  • What are the key geographies where research on Porphyria is being conducted?
  • Who are the key investors in this domain?
  • Who are the key opinion leaders / experts in this field?
  • What kind of partnership models are commonly adopted by industry stakeholders?
  • What are the factors that are likely to influence the evolution of this upcoming market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

TABLE OF CONTENTS

1. BACKGROUND

  • 1.1. Context
  • 1.2. Project Report

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. MARKET LANDSCAPE

  • 4.1. Market Landscape of Porphyria Drugs
  • 4.2. Market Landscape of Porphyria Drug Developers

5. CASE STUDY

  • 5.1 Case Study on Terminated and Dormant Programs

6. KEY MARKET INSIGHTS

  • 6.1. Clinical Trial Analysis
  • 6.2. KOL Analysis
  • 6.3. Company Competitiveness Analysis
  • 6.4. Publication Analysis
  • 6.6 Partnership and Collaborations

7. COMPANY PROFILES

  • 7.1. Agios Pharmaceuticals
  • 7.2. Alnylam Pharmaceuticals
  • 7.3. Clinuvel Pharmaceuticals
  • 7.4. Mitsubishi Tanabe Pharma
  • 7.5. Moderna Therapeutics
  • 7.6. Palatin Technologies
  • 7.7. Recordati Rare Diseases

8. MARKET FORECAST

  • 8.1. Drugs Forecasted and Sales Estimated
    • 8.1.1. GIVLAARI®
    • 8.1.2. Panhematin™
    • 8.1.3. SCENESSE®
    • 8.1.4. MT-7117
    • 8.1.5. Colestid
    • 8.1.6. HARVONI®
  • 8.2. Global Market Forecast, Till 2030
  • 8.3. Distribution by Drug Class
  • 8.4. Distribution by Type of Porphyria
  • 8.5. Distribution by Route of Administration
  • 8.6. Distribution by Region

9. APPENDICES

  • 9.1. Clinical Trial Analysis
  • 9.2. Publication Analysis
  • 9.3. List of Figures
  • 9.4. List of Companies and Organizations
  • 9.2. Publication Analysis
  • 9.3. List of Figures
  • 9.4. List of Companies and Organizations

List Of Figures

  • Figure 1.1 Distribution by Phase of Development
  • Figure 1.2 Distribution by Drug Class
  • Figure 1.3 Distribution by Phase of Development and Drug Class
  • Figure 1.4 Distribution by Type of Porphyria
  • Figure 1.5 Distribution by Type of Porphyria and Phase of Development
  • Figure 1.6 Distribution by Route of Administration
  • Figure 1.7 Distribution by Mechanism of Action
  • Figure 1.8 Distribution by Drug Designation Obtained
  • Figure 1.9 Distribution by Type of Player and Ownership
  • Figure 1.10 Distribution by Company Size
  • Figure 1.11 Distribution by Year of Establishment
  • Figure 1.12 Players in North America
  • Figure 1.13 Players in Europe
  • Figure 1.14 Players in Rest of the World
  • Figure 1.15 Distribution by Phase of Development and Location of Headquarters
  • Figure 1.16 Distribution by Type of Molecule and Location of Headquarters
  • Figure 1.17 Distribution by Phase of Development and Type of Molecule
  • Figure 3.1 Distribution by Trial Registration Year
  • Figure 3.2 Distribution by Trial Phase
  • Figure 3.3 Distribution by Trial Status
  • Figure 3.4 Analysis by Type of Sponsor
  • Figure 3.5 Key Industry Players
  • Figure 3.6 Key Non-industry Players
  • Figure 3.7 Distribution by Type of Porphyria
  • Figure 3.8 Distribution by Type of Sponsor and Type of Porphyria
  • Figure 3.9 Distribution by Trial Status and Type of Porphyria
  • Figure 3.10 Distribution by Enrolled Patients, Trial Status and Geography
  • Figure 3.11 Distribution by Trial Status and Geography
  • Figure 3.12 Distribution of Number of Trials by Geography
  • Figure 4.1 Distribution by Type of Organization
  • Figure 4.2 Distribution by Region
  • Figure 4.3 Distribution by Qualification
  • Figure 4.4 Distribution by Principal Investigator and Type of Porphyria
  • Figure 4.5 Distribution by Type of Porphyria
  • Figure 4.6 KOL Activeness V/S Strength: Scatter Plot
  • Figure 4.7 Roots Analysis vs Third Party Score
  • Figure 4.8 Roots Analysis vs Third Party Score
  • Figure 4.9 Regional Distribution
  • Figure 4.10 Activeness of KOLs Investigating Drugs in Clinical Studies
  • Figure 5.1 Benchmarking of Prominent Companies
  • Figure 5.2 Distribution by Developers
  • Figure 6.1 Distribution by Year of Publication
  • Figure 6.2 Distribution by Type of Porphyria
  • Figure 6.3 Distribution by Type of Porphyria and Year of Publication
  • Figure 6.4 Key Journals based on Publications Count
  • Figure 6.5 Word Cloud: Emerging Focus Areas
  • Figure 6.6 Distribution by Most Popular Authors
  • Figure 7.1 Distribution by Year of Collaboration
  • Figure 7.2 Distribution by Type of Collaboration
  • Figure 7.3 Distribution by Year of Collaboration and Type of Collaboration
  • Figure 7.4 Distribution by Key Players
  • Figure 7.5 Key Drugs by Number of Partnerships
  • Figure 7.6 Intercontinental and Intracontinental Agreements
  • Figure 9.1 GIVLAARI®: Global Sales Forecast, 2021-2030
  • Figure 9.2 GIVLAARI®: Regional Sales Forecast, 2021-2030
  • Figure 9.3 Panhematin®: Global Sales Forecast, 2021-2030
  • Figure 9.4 Panhematin®: Regional Sales Forecast, 2021-2030
  • Figure 9.5 SCENESSE®: Global Sales Forecast, 2021-2030
  • Figure 9.6 SCENESSE®: Regional Sales Forecast, 2021-2030
  • Figure 9.7 MT-7117: Global Sales Forecast, 2022-20301
  • Figure 9.8 MT-7117: Regional Sales Forecast, 2022-20301
  • Figure 9.9 Colestid: Global Sales Forecast, 2022-2030
  • Figure 9.10 Colestid: Regional Sales Forecast, 2022-2030
  • Figure 9.11 HARVONI®: Global Sales Forecast, 2025-2030
  • Figure 9.12 HARVONI®: Regional Sales Forecast, 2025-2030
  • Figure 9.13 Distribution by Type of Porphyria, 2021
  • Figure 9.14 Distribution by Type of Porphyria, 2030
  • Figure 9.15 Acute Hepatic Porphyria: Global Sales Forecast, 2021-2030
  • Figure 9.16 Acute Hepatic Porphyria: Regional Sales Forecast, 2021-2030
  • Figure 9.17 AIP: Global Sales Forecast, 2021-2030
  • Figure 9.18 AIP: Regional Sales Forecast, 2021-2030
  • Figure 9.19 EPP: Global Sales Forecast, 2025-2030
  • Figure 9.20 EPP: Regional Sales Forecast, 2021-2030
  • Figure 9.21 HCP: Global Sales Forecast, 2027-2030
  • Figure 9.22 HCP: Regional Sales Forecast, 2027-2030
  • Figure 9.23 PCT: Global Sales Forecast, 2025-2030
  • Figure 9.24 PCT: Regional Sales Forecast, 2025-2030
  • Figure 9.25 Variegate Porphyria: Global Sales Forecast, 2027-2030
  • Figure 9.26 Variegate Porphyria: Regional Sales Forecast, 2027-2030
  • Figure 9.27 X-Linked Porphyria: Global Sales Forecast, 2024-2030
  • Figure 9.28 X-Linked Porphyria: Regional Sales Forecast, 2024-2030
  • Figure 9.29 Distribution by Route of Administration, 2021
  • Figure 9.30 Distribution by Route of Administration, 2030
  • Figure 9.31 Oral: Global Sales Forecast, 2022-2030
  • Figure 9.32 Oral: Regional Sales Forecast, 2022-2030
  • Figure 9.33 Intravenous: Global Sales Forecast, 2021-2030
  • Figure 9.34 Intravenous: Regional Sales Forecast, 2021-2030
  • Figure 9.35 Subcutaneous: Global Sales Forecast, 2021-2030
  • Figure 9.36 Subcutaneous: Regional Sales Forecast, 2021-2030
  • Figure 9.37 Overall Market Opportunity, 2021-2030
  • Figure 9.38 Distribution by Type of Drug Class, 2021, 2025 and 2030
  • Figure 9.39 Regional Distribution, 2021,2025 and 2030
  • Figure 9.40 Country-wise Distribution (Bubble Chart Representation)

List Of Companies

The following companies and organizations have been mentioned in the report.

  • 1. Access Biotechnology
  • 2. Agios Pharmaceuticals
  • 3. Alexion Pharmaceuticals
  • 4. Alnylam Pharmaceuticals
  • 5. Association pour la recherche en medecine interne (armi)
  • 6. Atlas Molecular Pharma
  • 7. Atlas Ventures
  • 8. Atrium Health Wake Forest Baptist
  • 9. Beam Therapeutics
  • 10. Biotech Lab Singapore
  • 11. Bioprofarma Bago
  • 12. Blackstone
  • 13. Brigham and Women's Hospital
  • 14. Celnova Pharma
  • 15. Chiesi Farmaceutici
  • 16. Clinuvel Pharmaceuticals
  • 17. Committee for Medicinal Products of Human Use (CHMP)
  • 18. Cycle Pharmaceuticals
  • 19. Das Nationale Centrum für Tumorerkrankungen (NCT)
  • 20. Digna Biotech
  • 21. Disc Medicine
  • 22. FARMOVS
  • 23. Forge Biologics
  • 24. Gilead Sciences
  • 25. Hong Kong Winhealth Pharma Group
  • 26. Hospital Universitario 12 de Octubre
  • 27. Icahn School of Medicine
  • 28. Ironwood Pharmaceuticals
  • 29. Italchimici
  • 30. Lundbeck
  • 31. Medison Pharma
  • 32. Mitsubishi Tanabe Pharma
  • 33. Moderna Therapeutics
  • 34. Mount Sinai Morningside
  • 35. National Center for Research Resources (NCRR)
  • 36. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • 37. National Institutes of Health (NIH)
  • 38. NeuroDerm
  • 39. Nordlandssykehuset
  • 40. Novartis
  • 41. Novo Holdings
  • 42. Office of Rare Diseases (ORD)
  • 43. Palatin Technologies
  • 44. PANTHERx Rare
  • 45. PAREXEL
  • 46. Recordati Rare Diseases
  • 47. Roche
  • 48. Strasbourg University Hospital
  • 49. SurModics
  • 50. Taiba
  • 51. The Royal Norwegian Ministry of Health
  • 52. The University of Navarra
  • 53. The University of Texas
  • 54. The University of Texas Medical Branch
  • 55. Therapeutic Goods Administration (TGA)
  • 56. uniQure
  • 57. University of Alabama
  • 58. University of California
  • 59. University of South Florida
  • 60. University of Tromsø
  • 61. University of Utah